Loading
JPXHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
¥1,711
−¥4.00 · -0.23%
Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While its primary operations are in Japan, the company maintains an international presence through import and export activities, extending its reach to countries including the United States, Belgium, Finland, the Netherlands, Taiwan, and Thailand. Its extensive product lineup includes a wide array of immunoassay test kits designed for detecting pathogens such as influenza viruses, RS virus, human metapneumovirus, Streptococcus pneumoniae, Legionella, Mycoplasma pneumoniae, adenovirus, rotavirus, norovirus, and Group A streptococcus. Additionally, Mizuho Medy offers kits for pregnancy, ovulation, and fecal occult blood screening. The company also provides advanced tools like gene analysis instruments and specialized diagnostic kits for SARS-CoV-2 detection and Mycoplasma pneumoniae nucleic acid analysis.
Latest quote
¥1,711
−¥4.00 · -0.23%
Regular session · JST · Market data may be delayed.
Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While its primary operations are in Japan, the company maintains an international presence through import and export activities, extending its reach to countries including the United States, Belgium, Finland, the Netherlands, Taiwan, and Thailand. Its extensive product lineup includes a wide array of immunoassay test kits designed for detecting pathogens such as influenza viruses, RS virus, human metapneumovirus, Streptococcus pneumoniae, Legionella, Mycoplasma pneumoniae, adenovirus, rotavirus, norovirus, and Group A streptococcus. Additionally, Mizuho Medy offers kits for pregnancy, ovulation, and fecal occult blood screening. The company also provides advanced tools like gene analysis instruments and specialized diagnostic kits for SARS-CoV-2 detection and Mycoplasma pneumoniae nucleic acid analysis.
Day range
Current ¥1,711
52-week range
Current ¥1,711
Regular session · JST · Market data may be delayed.
Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While its primary operations are in Japan, the company maintains an international presence through import and export activities, extending its reach to countries including the United States, Belgium, Finland, the Netherlands, Taiwan, and Thailand. Its extensive product lineup includes a wide array of immunoassay test kits designed for detecting pathogens such as influenza viruses, RS virus, human metapneumovirus, Streptococcus pneumoniae, Legionella, Mycoplasma pneumoniae, adenovirus, rotavirus, norovirus, and Group A streptococcus. Additionally, Mizuho Medy offers kits for pregnancy, ovulation, and fecal occult blood screening. The company also provides advanced tools like gene analysis instruments and specialized diagnostic kits for SARS-CoV-2 detection and Mycoplasma pneumoniae nucleic acid analysis.
Day range
Current ¥1,711
52-week range
Current ¥1,711
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 11.26B JPY | 11.43B JPY | 10.99B JPY | 17.58B JPY | 12.89B JPY |
| Cost of goods sold | 3.48B JPY | 3.39B JPY | 2.96B JPY | 3.53B JPY | 3.28B JPY |
| Gross profit | 7.78B JPY | 8.04B JPY | 8.03B JPY | 14.05B JPY | 9.61B JPY |
| Research and development | 819M JPY | 783M JPY | 669.08M JPY | 605.47M JPY | 592.32M JPY |
| Selling, general, and administrative | 2.31B JPY | 2.34B JPY | 2.2B JPY | 2.34B JPY | 2.32B JPY |
| Operating expenses | 3.13B JPY | 3.12B JPY | 2.87B JPY | 2.94B JPY | 2.91B JPY |
| Interest income | 100M JPY | 75M JPY | 41.44M JPY | 9.47M JPY | 1.77M JPY |
| Interest expense | — | — | — | — | 1.24M JPY |
| Depreciation and amortization | 266M JPY | 186M JPY | 243.82M JPY | 157.78M JPY | 172.6M JPY |
| Operating income | 4.65B JPY | 4.92B JPY | 5.15B JPY | 11.1B JPY | 6.7B JPY |
| Net income | 3.43B JPY | 3.77B JPY | 3.77B JPY | 7.84B JPY | 4.82B JPY |
Company facts updated Sep 6, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
iShares International Small-Cap Equity Factor ETFISCF477.71K0.07%676.28M USD0.24%$46.18+0.34%
WisdomTree Dynamic International Equity FundDDWM310.49K0.02%1.48B USD0.40%$47.60-0.08%
Dimensional - International Core Equity 2 ETFDFIC272.56K0.00%15.37B USD0.22%$39.475-0.01%
Dimensional - International Small Cap ETFDFIS257.11K0.00%5.86B USD0.39%$37.67+0.13%
Dimensional - International Core Equity Market ETFDFAI194.22K0.00%18.17B USD0.18%$43.41-0.07%
WisdomTree Japan SmallCap Dividend FundDFJ171.53K0.04%430.84M USD0.58%$115.31-0.10%
Dimensional World ex U.S. Core Equity 2 ETFDFAX128.01K0.00%12.55B USD0.28%$38.61+0.44%
WisdomTree International Equity FundDWM104.22K0.02%684.94M USD0.48%$76.515-0.18%iShares International Small-Cap Equity Factor ETFISCFWisdomTree Dynamic International Equity FundDDWMDimensional - International Core Equity 2 ETFDFICDimensional - International Small Cap ETFDFISDimensional - International Core Equity Market ETFDFAIWisdomTree Japan SmallCap Dividend FundDFJDimensional World ex U.S. Core Equity 2 ETFDFAXWisdomTree International Equity FundDWMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
